A Study of Niraparib in Patients With Relapsed Ovarian Cancer

NCT04392102 | Completed Phase 2

• 1 other identifier: ZL-2306-008
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 7

Brief Summary

This is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received three or four previous chemotherapy regimens. Niraparib is an orally active PARP inhibitor. Niraparib will be administered once daily continuously during a 28-day cycle. Health-related quality of life will be measured by Eastern Cooperative Oncology Group performance status (ECOG). Safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), RECIST tumor assessments and safety laboratory values.

Conditions

Ovarian Cancer

Outcome Measures

Primary Outcomes (1)

• Objective Response Rate（ORR）

  The ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) as assessed by the Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) (version1.1).

  Up to 3 years

Secondary Outcomes (5)

• Duration of Response (DoR)

  Up to 3 years

• Disease Control Rate (DCR)

  Up to 3 years

• Progression Free Survival (PFS)

  Up to 3 years

• Overall Survival (OS)

  Up to 3 years

• Number of Participants With Any Non-serious Adverse Event (Non-SAE) or Any SAE To evaluate the safety and tolerability of niraparib

  Up to 3 years

Study Arms (1)

ZL-2306(Niraparib)

EXPERIMENTAL

The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count

Drug: ZL-2306(Niraparib）

Interventions

ZL-2306(Niraparib） DRUG

The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count

Also known as: Zejula

ZL-2306(Niraparib)

Eligibility Criteria

• Age: 18 Years+
• Gender Eligibility Details: Patients must be female and at least 18 years of age
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Patients must be female and at least 18 years of age
• \. Patients must provide written informed consent
• \. Patients must be gBRCA mutation or HRD positive
• \. Patients must have histologically diagnosed high-grade (Grade 2 or 3)serous epithelial ovarian, fallopian tube, or primary peritoneal cancer with recurrent disease.
• \. Patients Must have completed 3 or 4 previous chemotherapy regimens.
• \. Patients must have measurable disease according to RECIST (v.1.1).
• \. Patients must have an Eastern Cooperative Oncology Group(ECOG) performance status of 0 or1
• \. Patients must have adequate organ function, defined as follows: a. Absolute neutrophil count≥1500/ul b. Platelets ≥150000/ul c. Hemoglobin≥10g/dL d. Serum creatinine≤1.5X upper limit of normal (ULN)or calculated creatinine clearance≥60ml/min using the Cockcroft-Gault equation e. Total bilirubin≤1.5X ULN OR direct bilirubin≤1X ULN f. Aspartate aminotransferase and alanine aminotransferase≤2.5X ULN unless liver metastases are present, in which case they must be ≤5X ULN
• \. Patients must be either postmenopausal, free from menses for\>12 months, surgically sterilized, or willing to use adequate contraception to prevent pregnancy or must agree to abstain from heterosexual activity throughout the study, starting with enrollment through 90 days after the last dose of study treatment
• \. Patients must have formalin-fixed, paraffin-embedded tumor samples available form primary or recurrent cancer.
• \. Patients must be able to take oral medications and capable of complying with treatment and follow up visit

You may not qualify if:

• \. Patients who have received other investigational drugs within 4 weeks or 5X t1/2 before first dose of study treatment.
• \. Patients have had palliative radiotherapy encompassing\>20% of the bone marrow within 3 weeks of the first dose of study treatment.
• \. Patients have any known, persistent(\>4 weeks)，≥Grade 3 anemia, neutrophil count decrease or platelet count decrease during the last chemotherapy.
• \. Patients have any known, persistent (\>4 weeks), ≥ Grade 3 fatigue during the last chemotherapy.
• \. Patients have received pelvic radiotherapy as treatment for primary or recurrent disease within 1 year of the first dose of study treatment.
• \. Patients have symptomatic uncontrolled brain or leptomeningeal metastases. The patient have new or progressive signs or symptoms related to the CNS disease and not taking a stable dose of steroids or no steroids. A scan to confirm the absence of brain metastases is not required.
• \. Patients have known hypersensitivity to the components of niraparib
• \. Patient have had major surgery within 3 weeks of fist dose treatment and patient must have recovered form any effects of any major surgery
• \. Patients have had diagnosis, detection, or treatment of invasive cancer other than ovarian cancer ≤2 years prior to enrollment(except basal or squamous cell carcinoma of the skin that has been definitively treated)
• \. Patients are considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to: 1. uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction 2. uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome or any psychiatric disorder that prohibits obtaining informed consent 3. immune deficiency (not including splenectomy) 4. HIV infection or active hepatitis(i.e. hepatitis B with HBV-DNA\>500IU/ml or hepatitis C with positive HCV-RNA).
• \. Patients have received a transfusion (platelets or red blood cells) within 4 weeks of the first dose of study treatment.
• \. Patients have known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
• \. Patients have current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study or interfere with patient's participation for the full duration of the study treatment or that makes it not in the best interest of the patient to participate

Sponsors & Collaborators

• Zai Lab (Shanghai) Co., Ltd.: lead

Study Sites (7)

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Location

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

Location

Sun Yat-sen Memorial Hospital,Sun Yat-sen University

Guangzhou, Guangdong, China

Location

Harbin Medical University

Haerbin, Heilongjiang, China

Location

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Location

West China Second Iniversity Hospital

Chengdu, Sichuan, China

Location

Sir Run Shaw Hospital, school of medicine, Zhejiang University

Guangzhou, Zhejiang, China

Location

MeSH Terms

Conditions

Ovarian Neoplasms

Interventions

niraparib

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders

Study Officials

• Rutie Yin

  West China Second University Hospital

  PRINCIPAL INVESTIGATOR

• Xiaohua Wu

  Fudan University

  PRINCIPAL INVESTIGATOR

• Hong Zheng

  Peking University Cancer Hospital & Institute

  PRINCIPAL INVESTIGATOR

• Ge Lou

  Harbin Medical University

  PRINCIPAL INVESTIGATOR

• Lingying Wu

  Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  PRINCIPAL INVESTIGATOR

• Hongmin Pan

  Sir Run Shaw Hospital, school of medicine, Zhejiang University

  PRINCIPAL INVESTIGATOR

• Zhongqiu Lin

  Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 13, 2020
• First Posted: May 18, 2020
• Study Start: August 4, 2020
• Primary Completion: April 8, 2021
• Study Completion: August 11, 2022
• Last Updated: August 29, 2022

Record last verified: 2022-08

Locations

CN (7)